Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2024年9月26日 - 4:48AM
Edgar (US Regulatory)
Filed Pursuant to Rule 433
Registration Statement No. 333-262557
ACCELERATED RETURN NOTES® (ARNs®)
|
|
ARNs® Linked to the SPDR® S&P® Biotech ETF
|
|
Issuer
|
|
The Toronto-Dominion Bank (“TD”)
|
|
Principal Amount
|
|
$10.00 per unit
|
|
Term
|
|
Approximately fourteen months
|
|
Market Measure
|
|
The SPDR® S&P® Biotech ETF (Bloomberg symbol: “XBI”)
|
|
Payout Profile at Maturity
|
|
• 3-to-1 upside exposure to increases in the Market Measure, subject to the Capped Value
• 1-to-1 downside exposure to decreases in the Market Measure, with up to 100.00% of your principal at risk
|
|
Participation Rate
|
|
300.00%
|
|
Capped Value
|
|
[$12.20 to $12.60] per unit, a [22.00% to 26.00%] return over the principal amount, to be determined on the pricing date
|
|
Investment Considerations
|
|
This investment is designed for investors who anticipate that the Market Measure will increase moderately over the term of the notes, and are willing to accept a capped return, take full downside risk and
forgo interim interest payments.
|
|
Preliminary Offering
Documents
|
|
|
|
Exchange Listing
|
|
No
|
You should read the relevant Preliminary Offering Documents before you invest. Click on the Preliminary Offering Documents hyperlink above or call your
Financial Advisor for a hard copy.
Risk Factors
Please see the Preliminary Offering Documents for a description of certain risks related to this investment, including, but not limited to, the following:
• |
Depending on the performance of the Market Measure as measured shortly before the maturity date, your investment may result in a loss; there is no guaranteed return of principal.
|
• |
Payments on the notes are subject to the credit risk of TD, and actual or perceived changes in the creditworthiness of TD are expected to affect the value of the notes. If TD becomes unable to meet its
financial obligations as they become due, you may lose some or all of your investment.
|
• |
Your investment return is limited to the return represented by the Capped Value and may be less than a comparable investment directly in the Market Measure or the securities held by the Market Measure.
|
• |
The initial estimated value of the notes on the pricing date will be less than their public offering price.
|
• |
The initial estimated value of your notes is not a prediction of the prices at which you may sell your notes in the secondary market, if any exists, and such secondary market prices, if any, will likely
be less than the public offering price of your notes, may be less than the initial estimated value of your notes and could result in a substantial loss to you.
|
• |
You will have no rights of a holder of the Market Measure or the securities held by the Market Measure, and you will not be entitled to receive any shares of the Market Measure or the securities held by
the Market Measure, or any dividends or other distributions in respect of the Market Measure or the securities held by the Market Measure.
|
• |
There are liquidity and management risks associated with the Market Measure.
|
• |
The performance of the Market Measure may not correlate with the performance of its underlying index as well as the net asset value per share of the Market Measure, especially during periods of market
volatility when the liquidity and the market price of the shares of the Market Measure and/or the securities held by the Market Measure may be adversely affected, sometimes materially.
|
• |
Payments on the notes will not be adjusted for all corporate events that could affect the Market Measure.
|
• |
The stocks held by the Underlying Fund are concentrated in one sector.
|
• |
Adverse conditions in the biotechnology sector may reduce your return on the notes.
|
• |
The sponsor or investment advisor of the Underlying Fund may adjust the Underlying Fund in a way that affects its prices, and the sponsor or investment advisor has no obligation to consider your
interests.
|
Final terms will be set on the pricing date within the given range for the specified Market-Linked Investment. Please see the Preliminary Offering Documents for complete product disclosure,
including related risks and tax disclosure.
The graph above and the table below reflect the hypothetical return on the notes, based on the terms contained in the table to
the left (using the mid-point for any range(s)). The graph and table have been prepared for purposes of illustration only and do not take into account any tax consequences from investing in the notes.
|
Hypothetical
Percentage Change
from the Starting
Value to the Ending
Value
|
Hypothetical
Redemption
Amount per Unit
|
Hypothetical Total
Rate of Return on
the Notes
|
-100.00%
|
$0.00
|
-100.00%
|
-75.00%
|
$2.50
|
-75.00%
|
-50.00%
|
$5.00
|
-50.00%
|
-40.00%
|
$6.00
|
-40.00%
|
-30.00%
|
$7.00
|
-30.00%
|
-20.00%
|
$8.00
|
-20.00%
|
-10.00%
|
$9.00
|
-10.00%
|
-5.00%
|
$9.50
|
-5.00%
|
0.00%
|
$10.00
|
0.00%
|
2.00%
|
$10.60
|
6.00%
|
4.00%
|
$11.20
|
12.00%
|
6.00%
|
$11.80
|
18.00%
|
8.00%
|
$12.40(1)
|
24.00%
|
10.00%
|
$12.40
|
24.00%
|
20.00%
|
$12.40
|
24.00%
|
30.00%
|
$12.40
|
24.00%
|
40.00%
|
$12.40
|
24.00%
|
50.00%
|
$12.40
|
24.00%
|
(1)
|
The Redemption Amount per unit cannot exceed the hypothetical Capped Value.
|
TD has filed a registration statement (including a product supplement and a prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this term sheet relates. Before you invest, you should read
the Note Prospectus, including this term sheet, and the other documents that TD has filed with the SEC, for more complete information about TD and this offering. You may get these documents without cost by visiting EDGAR on the SEC
website at www.sec.gov. Alternatively, TD, any agent, or any dealer participating in this offering will arrange to send you these documents if you so request by calling MLPF&S or BofAS toll-free at 1-800-294-1322.
Toronto Dominion Bank (NYSE:TD)
過去 株価チャート
から 9 2024 まで 10 2024
Toronto Dominion Bank (NYSE:TD)
過去 株価チャート
から 10 2023 まで 10 2024